Aster DM Quality Care Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Aster DM Quality Care Ltd filed with BSE on 08 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aster DM Healthcare reported Q4 FY26 revenue of INR 1,182 crores, up 18% year-on-year, with operating EBITDA of INR 244 crores, up 26%, and margins of 20.7%. Management also presented combined proforma performance with Quality Care India Limited (QCIL), which reported revenue of INR 1,178 crores in Q4 FY26 with EBITDA of INR 272 crores, as the proposed merger progressed to the final NCLT approval stage. Both companies detailed cluster-wise performance, capacity expansion plans, and cost synergies, including a Kerala nurses' wage settlement reached during the quarter.
Numbers mentioned
Revenue from operations: INR 1,182 crores (Q4 FY26)
p. 5
“Revenue from operations stood at INR 1,182 crores, reflecting an 18% year-on-year increase.”
Alisha Moopen, page 5 of the filed PDF · View the filing
Operating EBITDA: INR 244 crores (Q4 FY26)
p. 5
“Operating EBITDA for the quarter stood at INR 244 crores, growing 26% year-on-year, with margins at 20.7% despite the addition of new capacity.”
Alisha Moopen, page 5 of the filed PDF · View the filing
Combined proforma revenue (Aster + QCIL): INR 2,361 crores (Q4 FY26)
p. 3
“the revenues have grown 18% year-on-year to INR 2,361 crores for the quarter, supported by a 12% increase in total patient volumes and an 8% improvement in ARPP IP.”
Alisha Moopen, page 3 of the filed PDF · View the filing
Combined proforma Operating EBITDA: INR 517 crores (Q4 FY26)
p. 3
“Operating EBITDA has outpaced the revenue growth, increasing by 25% to INR 517 crores.”
Alisha Moopen, page 3 of the filed PDF · View the filing
Combined proforma full year revenue: INR 9,273 crores (FY26)
p. 4
“For FY26, the combined platform has delivered revenue of INR 9,273 crores, growing 14% year-on-year, with growth supported by a balanced increase both in patient volumes as well as ARPP IP.”
Alisha Moopen, page 4 of the filed PDF · View the filing
QCIL Q4 revenue: INR 1,178 crores (Q4 FY26)
p. 8
“Q4 FY26 witnessed a strong growth overall with a Revenue growth by 18% year-on-year to INR 1,178 crores.”
Varun Khanna, page 8 of the filed PDF · View the filing
QCIL Q4 EBITDA: INR 272 crores (Q4 FY26)
p. 8
“EBITDA grew 23% year-on-year to INR 272 crores.”
Varun Khanna, page 8 of the filed PDF · View the filing
QCIL full year EBITDA: INR 1,066 crores (FY26)
p. 8
“QCIL recorded an EBITDA of INR 1,066 crores, first time ever breaching the INR 1,000 crores mark, which represents a growth of 24.1% year-on-year.”
Varun Khanna, page 8 of the filed PDF · View the filing
Normalised PAT (Post NCI): INR 153 crores (Q4 FY26)
p. 11
“Normalised PAT (Post NCI) for the quarter stood at INR 153 crores, compared to INR 106 crores in Q4 FY25, reflecting a growth of 45% year-on-year.”
Sunil Kumar, page 11 of the filed PDF · View the filing
Capital expenditure: INR 549 crores (FY26)
p. 12
“For the year ended 31st March 2026, our capital expenditure stood at INR 549 crores, with approximately 45% allocated towards expansion projects.”
Sunil Kumar, page 12 of the filed PDF · View the filing
Gross debt: INR 701 crores (as of March 31, 2026)
p. 12
“we continue to maintain a robust liquidity position, with cash and cash equivalents of INR 1,327 crores, while our gross debt remains moderate at INR 701 crores.”
Sunil Kumar, page 12 of the filed PDF · View the filing
Total bed capacity (Aster): 5,449 beds (as of March 31, 2026)
p. 6
“Over the past year, we added 290 beds, taking Aster’s total capacity to 5,449 beds as of March 31, 2026, and expanding our India network to 20 hospitals, including Kasargod.”
Alisha Moopen, page 6 of the filed PDF · View the filing
Shareholder approval for merger: 96.7% votes in favor (Q4 FY26)
p. 4
“During the quarter, the merger received overwhelming approval from shareholders and creditors, with 96.7% of shareholder votes cast in favor, reflecting strong alignment and confidence in the strategic direction.”
Alisha Moopen, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
NCLT merger approval / effectiveness — merger effective · this quarter
stated conditionally by Alisha Moopen
p. 4
“Based on current timelines, we expect the process to be completed within this quarter.”
Alisha Moopen, page 4 of the filed PDF · View the filing
Aster bed capacity expansion — over 8,150 beds · coming years
stated firmly by Alisha Moopen
p. 6
“we plan to add nearly 2,500 beds over the coming years through a balanced mix of greenfield and brownfield expansions, which will take our total capacity to over 8,150 beds.”
Alisha Moopen, page 6 of the filed PDF · View the filing
QCIL bed capacity expansion — over 1,700 beds, ~INR 2,000 crores investment · next 3-4 years
stated firmly by Varun Khanna
p. 9
“We have upgraded our near-term to mid-term expansion plans and intend to invest close to INR 2,000 crores to add over 1,700 beds in the next 3-4 years”
Varun Khanna, page 9 of the filed PDF · View the filing
CONGO mix — 60% and then 65%
stated as an aspiration by Alisha Moopen
p. 14
“We are sitting at, I think, a blended level now, 55% CONGO contribution. We think we can definitely take it up to 60% and then 65% as well.”
Alisha Moopen, page 14 of the filed PDF · View the filing
Aster capex — ~2,500 beds at cost of INR 2,700 crores · next four years
stated firmly by Sunil Kumar
p. 12
“Over the next four years, we plan to add ~2,500 beds at the cost of INR 2700 crores.”
Sunil Kumar, page 12 of the filed PDF · View the filing
K&M cluster IP volume growth — mid to high single digit · next one to two quarters
stated conditionally by Sunil Kumar
p. 19
“So, we don't expect this to be the norm. So, we expect to go to mid to high single digit.”
Sunil Kumar, page 19 of the filed PDF · View the filing
QCIL top-line growth and margin expansion — next two years
stated as an aspiration by Varun Khanna
p. 21
“Yes, I do. I mean, we've gone to a solid start, and I do see that the margin expansion as well as the top line growth will continue.”
Varun Khanna, page 21 of the filed PDF · View the filing
Aster margin trajectory FY27 — FY27
stated conditionally by Sunil Kumar
p. 18
“we don't expect any margin dilution and year-on-year we'll grow in the margins.”
Sunil Kumar, page 18 of the filed PDF · View the filing
QCIL CAPEX spend ratio — 5% of annual revenue
stated firmly by Varun Khanna
p. 20
“Outside of that, our guidance on CAPEX has always been clear. We've stuck to the same number. 5% is the CAPEX spend when it comes to the 20 Aster DM Healthcare Limited – Q4 and full year FY26 Earnings Conference Call annual CAPEX spend to spruce up the existing facility or to add clinical programs.”
Varun Khanna, page 20 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Khanna said the industry has concerns around data privacy and transparency, and that adoption cannot be forced on hospitals.
Answered by Varun Khanna
Asked by Tausif Shaikh: Whether common insurance empanelment platforms are a threat to private hospital chains.
p. 13
“It can only be done if private hospitals want to accept it.”
Varun Khanna, page 13 of the filed PDF · View the filing
Ramesh Kumar explained the strike began over demands for a government wage notification and was settled after negotiation on April 13th.
Answered by Ramesh Kumar
Asked by Tausif Shaikh: Status of the Kerala nurses' strike and wage settlement.
p. 13
“On April 13th, we have come to a settlement with them. And yeah, the strike is called off.”
Ramesh Kumar, page 13 of the filed PDF · View the filing
T J Wilson said the total impact was INR 5-6 crores with varying per-nurse increments across hospitals.
Answered by T.J. Wilson
Asked by Tausif Shaikh: Financial impact of the nurses' wage increase in Kerala.
p. 14
“Our total impact in Kerala will be INR 5–6 crores.”
T.J. Wilson, page 14 of the filed PDF · View the filing
Sunil Kumar cited doctor acquisition as the primary driver, and Alisha Moopen said CONGO mix could rise from 55% toward 60-65%.
Answered by Sunil Kumar
Asked by Damayanti Kerai: What is driving ARPOB and IP volume growth, and headroom for CONGO-T contribution.
p. 14
“We have added 36+ new doctors in the last 6 months alone.”
Sunil Kumar, page 14 of the filed PDF · View the filing
Khanna said mature units are growing via CONGO-T enhancement including oncology, while focus and emerging units still have runway on EBITDA margin improvement.
Answered by Varun Khanna
Asked by Kunal Randeria: Growth drivers for QCIL's mature, focus and emerging units going forward.
p. 16
“Our mature hospitals are currently growing 13.5 -14% on the top and 20-plus percent on the bottom line.”
Varun Khanna, page 16 of the filed PDF · View the filing
Khanna clarified the synergies disclosed were from combining Care, Evercare and KIMS within QCIL, not yet from the Aster-QCIL merger.
Answered by Varun Khanna
Asked by Kunal Randeria: Nature of the INR 85 crore synergies reported and whether more synergies will come post-merger.
p. 17
“We've still not started the work on Aster QCIL synergies really, and they will start to flow in post-merger.”
Varun Khanna, page 17 of the filed PDF · View the filing
Sunil Kumar attributed it to exiting a low-yield government scheme at Aster Aadhar and to the Whitefield hospital maturing off a high base, plus temporary clinician attrition.
Answered by Sunil Kumar
Asked by Siddharth Negandhi: Why Karnataka IP volume growth was slower than the group average.
p. 18
“As I have called out very clearly, what we exited is a low-yield schemes.”
Sunil Kumar, page 18 of the filed PDF · View the filing
Khanna described ongoing asset-by-asset turnaround investments in Hyderabad and reiterated the 5% of revenue capex framework.
Answered by Varun Khanna
Asked by Amey Chalke: Status of the planned Hyderabad cluster investment and QCIL capex guidance.
p. 20
“the work that we are doing in Hyderabad is turning every asset around.”
Varun Khanna, page 20 of the filed PDF · View the filing
Sunil Kumar attributed growth to Narayanadri Hospital's ramp-up and Ramesh Hospitals' clinician additions after a low base.
Answered by Sunil Kumar
Asked by Vivek Sethia: Drivers of the strong Andhra Pradesh and Telangana cluster performance and sustainability.
p. 22
“Even in the current year, we've seen a 46% growth in the revenue and almost 75% plus growth in EBITDA.”
Sunil Kumar, page 22 of the filed PDF · View the filing
Khanna gave a range of INR 0.8-1.1 crores per bed for brownfield and INR 1.5-1.6 crores for greenfield.
Answered by Varun Khanna
Asked by Vivek Sethia: Per-bed capex for QCIL's brownfield and greenfield expansion.
p. 23
“the broad range for brownfield will be between INR 0.8 to 1.1 crores and for greenfield could be about INR 1.5- 1.6 crores.”
Varun Khanna, page 23 of the filed PDF · View the filing
Sunil Kumar attributed the gap to one-time merger-related and consultancy costs.
Answered by Sunil Kumar
Asked by Vivek Sethia: Discrepancy between reported QCIL EBITDA margin and the figure in QCIL's annual report.
p. 24
“there is this one time that impacts us broadly around, the one time that we're doing on merger and also some of the work that we're doing with consultants to enhance the productivity.”
Sunil Kumar, page 24 of the filed PDF · View the filing
Risks flagged
Nurses' strike in Kerala over wage demands
p. 13
“When we talk about minimum wages and the strike that happened in Kerala, this started sometime in the mid of March.”
Ramesh Kumar, page 13 of the filed PDF · View the filing
Decline in medical value travel patients from UAE and Oman due to macro headwinds
p. 13
“in the Middle East we have found that especially, from Oman and UAE less number of patients are flowing in”
Ramesh Kumar, page 13 of the filed PDF · View the filing
Loss of revenue from exiting low-yielding government schemes at Aster Aadhar
p. 18
“what we exited is a low-yield schemes. I think we have very clearly called out, it is a government scheme, it is a low-yield scheme.”
Sunil Kumar, page 18 of the filed PDF · View the filing
Capacity bottleneck limiting growth at Aster Aadhar
p. 18
“one of the reasons we exited also is that there's a capacity bottleneck in Aster Aadhar.”
Sunil Kumar, page 18 of the filed PDF · View the filing
Competitive intensity for clinical talent in the Karnataka market
p. 18
“we also had competition intensity, especially in the north of Bangalore. We had attrition of one or two teams also.”
Sunil Kumar, page 18 of the filed PDF · View the filing
Merger completion remains subject to NCLT approval
p. 3
“It is to be noted that the merger is subject to further regulatory approvals.”
Puneet Maheshwari, page 3 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.